Statement: Between the patients in the primary trial and the secondary trial, only 1.56% suffered from sepsis.
Primary_evidence: Adverse Events 1:   Total: 0/161 (0.00%)   Gastrointestinal-Other 0/161 (0.00%)   Dehydration 0/161 (0.00%)   Renal/Genitourinary-Other 0/161 (0.00%) Adverse Events 2:   Total: 1/64 (1.56%)   Gastrointestinal-Other 1/64 (1.56%)   Dehydration 1/64 (1.56%)   Renal/Genitourinary-Other 1/64 (1.56%)
Secondary_evidence: Adverse Events 1:   Total: 13/34 (38.24%)   Anemia 3/34 (8.82%)   Diarrhea 7/34 (20.59%)   Nausea 2/34 (5.88%)   Sepsis 1/34 (2.94%)   Urinary tract infection 1/34 (2.94%)   Alkaline phosphatase increased 1/34 (2.94%)   Neutrophil count decreased 2/34 (5.88%)   Dehydration 1/34 (2.94%)   Headache 1/34 (2.94%)   Thromboembolic event 1/34 (2.94%)